HomeCompareCMBNF vs JNJ

CMBNF vs JNJ: Dividend Comparison 2026

CMBNF yields 5.80% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMBNF wins by $8.6K in total portfolio value
10 years
CMBNF
CMBNF
● Live price
5.80%
Share price
$91.31
Annual div
$5.30
5Y div CAGR
10.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.9K
Annual income
$2,955.99
Full CMBNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CMBNF vs JNJ

📍 CMBNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMBNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMBNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMBNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMBNF
Annual income on $10K today (after 15% tax)
$492.94/yr
After 10yr DRIP, annual income (after tax)
$2,512.59/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,473.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMBNF + JNJ for your $10,000?

CMBNF: 50%JNJ: 50%
100% JNJ50/50100% CMBNF
Portfolio after 10yr
$34.6K
Annual income
$3,822.70/yr
Blended yield
11.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CMBNF
No analyst data
Altman Z
0.1
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMBNF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMBNFJNJ
Forward yield5.80%2.13%
Annual dividend / share$5.30$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.8%28%
Portfolio after 10y$38.9K$30.3K
Annual income after 10y$2,955.99$4,689.40
Total dividends collected$15.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CMBNF vs JNJ ($10,000, DRIP)

YearCMBNF PortfolioCMBNF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,343$642.56$10,592$272.30+$751.00CMBNF
2$12,891$754.71$11,289$357.73+$1.6KCMBNF
3$14,682$888.21$12,123$472.89+$2.6KCMBNF
4$16,757$1,047.51$13,141$629.86+$3.6KCMBNF
5$19,168$1,238.04$14,408$846.81+$4.8KCMBNF
6$21,976$1,466.46$16,021$1,151.60+$6.0KCMBNF
7$25,256$1,741.02$18,122$1,588.22+$7.1KCMBNF
8$29,095$2,071.87$20,930$2,228.20+$8.2KCMBNF
9$33,604$2,471.64$24,792$3,191.91+$8.8KCMBNF
10$38,912$2,955.99$30,274$4,689.40+$8.6KCMBNF

CMBNF vs JNJ: Complete Analysis 2026

CMBNFStock

Cembra Money Bank AG provides consumer finance products and services in Switzerland. The company offers savings products, including medium-term notes and deposit accounts; loans comprising cash, consumer, personal, business, and auto loans; credit card receivables; and leasing services for new and used vehicles, including cars, light commercial vehicles, motorcycles, and caravans, as well as corporate leasing services. It also provides financial protection products in case of involuntary unemployment, accident, illness, or disability; travel and flight, and card protection insurance products; investment products; and credit cards, mobile payment, and e-services. In addition, the company offers financing solutions to small businesses under the Cembra Business brand, as well as invoice financing services. The company serves private and self-employed individuals, and small and medium enterprises. It operates through a network of branches, as well as through various sales channels, such as the internet, credit card partners, independent intermediaries, and approximately 4,000 car dealers. The company was formerly known as GE Money Bank Aktiengesellschaft and changed its name to Cembra Money Bank AG in October 2013. Cembra Money Bank AG was founded in 1912 and is headquartered in Zurich, Switzerland.

Full CMBNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CMBNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMBNF vs SCHDCMBNF vs JEPICMBNF vs OCMBNF vs KOCMBNF vs MAINCMBNF vs ABBVCMBNF vs MRKCMBNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.